Patents by Inventor Tod Woolf

Tod Woolf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide compositions with enhanced efficiency
    Patent number: 10626398
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Grant
    Filed: January 21, 2019
    Date of Patent: April 21, 2020
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Tod Woolf, Margaret Taylor
  • OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY
    Publication number: 20190316138
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Application
    Filed: January 21, 2019
    Publication date: October 17, 2019
    Inventors: Tod Woolf, Margaret Taylor
  • Oligonucleotide compositions with enhanced efficiency
    Patent number: 10196640
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: February 5, 2019
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Tod Woolf, Margaret Taylor
  • OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY
    Publication number: 20190017051
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Application
    Filed: June 21, 2018
    Publication date: January 17, 2019
    Inventors: Tod WOOLF, Margaret TAYLOR
  • DOUBLE-STRANDED OLIGONUCLEOTIDES
    Publication number: 20190002880
    Abstract: Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.
    Type: Application
    Filed: September 14, 2018
    Publication date: January 3, 2019
    Inventors: Tod Woolf, Kristin Wiederholt
  • Double-stranded oligonucleotides
    Patent number: 10106793
    Abstract: Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: October 23, 2018
    Assignee: Life Technologies Corporation
    Inventors: Tod Woolf, Kristin Wiederholt
  • Oligonucleotide compositions with enhanced efficiency
    Patent number: 10036025
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: July 31, 2018
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Tod Woolf, Margaret Taylor
  • OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY
    Publication number: 20180087056
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Application
    Filed: October 3, 2017
    Publication date: March 29, 2018
    Inventors: Tod WOOLF, Margaret TAYLOR
  • OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY
    Publication number: 20170321219
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Application
    Filed: July 17, 2017
    Publication date: November 9, 2017
    Inventors: Tod WOOLF, Margaret Taylor
  • Oligonucleotide compositions with enhanced efficiency
    Patent number: 9796978
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: October 24, 2017
    Assignee: LIFE TECHNOLOGIES CORPORATION
    Inventors: Tod Woolf, Margaret Taylor
  • Oligonucleotide compositions with enhanced efficiency
    Patent number: 9777275
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: October 3, 2017
    Assignee: Life Technologies Corporation
    Inventors: Tod Woolf, Margaret Taylor
  • DOUBLE-STRANDED OLIGONUCLEOTIDES
    Publication number: 20170137816
    Abstract: Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.
    Type: Application
    Filed: January 27, 2017
    Publication date: May 18, 2017
    Inventors: Tod WOOLF, Kristin Wiederholt
  • Double-stranded oligonucleotides
    Patent number: 9592250
    Abstract: Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.
    Type: Grant
    Filed: July 29, 2014
    Date of Patent: March 14, 2017
    Assignee: Life Technologies Corporation
    Inventors: Tod Woolf, Kristin Wiederholt
  • OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY
    Publication number: 20150099797
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 9, 2015
    Inventors: Tod WOOLF, Margaret Taylor
  • DOUBLE-STRANDED OLIGONUCLEOTIDES
    Publication number: 20150057333
    Abstract: Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.
    Type: Application
    Filed: July 29, 2014
    Publication date: February 26, 2015
    Inventors: TOD WOOLF, KRISTIN WIEDERHOLT
  • Double-stranded oligonucleotides
    Patent number: 8815821
    Abstract: Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.
    Type: Grant
    Filed: October 20, 2011
    Date of Patent: August 26, 2014
    Assignee: Life Technologies Corporation
    Inventor: Tod Woolf
  • OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY
    Publication number: 20130303586
    Abstract: The oligonucleotide compositions of the present invention make use of combinations of oligonucleotides. In one aspect, the invention features an oligonucleotide composition including at least 2 different oligonucleotides targeted to a target gene. This invention also provides methods of inhibiting protein synthesis in a cell and methods of identifying oligonucleotide compositions that inhibit synthesis of a protein in a cell.
    Type: Application
    Filed: March 13, 2013
    Publication date: November 14, 2013
    Inventors: Tod Woolf, Margaret Taylor
  • SENSE mRNA THERAPY
    Publication number: 20090093433
    Abstract: The present invention describes novel methods for the stabilization of mRNA. These alterations increase stability of mRNA and enable its use in sense RNA therapy to transiantly express proteins in a cell. Accordingly, the present invention is directed to methods for making such modifications, compositions comprising such modifications, and the use of such compositions in treating disease states.
    Type: Application
    Filed: August 1, 2008
    Publication date: April 9, 2009
    Applicant: INVITROGEN CORPORATION
    Inventors: Tod Woolf, Kristin Wiederholt, Margaret Taylor
  • Double-Stranded Oligonucleotides
    Publication number: 20090023216
    Abstract: Antisense sequences, including duplex RNAi compositions, which possess improved properties over those taught in the prior art are disclosed. The invention provides optimized antisense oligomer compositions and method for making and using the both in in vitro systems and therapeutically. The invention also provides methods of making and using the improved antisense oligomer compositions.
    Type: Application
    Filed: July 11, 2007
    Publication date: January 22, 2009
    Applicant: INVITROGEN CORPORATION
    Inventor: Tod Woolf
  • 'signalin' family of TGFbeta signal transduction proteins and uses related thereto
    Publication number: 20070117098
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here signalin-related genes, which are involved in a signal transduction induced by members of the TGF? superfamily. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Application
    Filed: October 14, 2005
    Publication date: May 24, 2007
    Applicants: Curis, Inc., President and Fellows of Harvard College
    Inventors: Jonathan Graff, Tod Woolf, Ping Jin, Douglas Melton